SecBot SecBot
EFFECT ·Filed Jul 13, 2026

CBIO

CRESCENT BIOPHARMA, INC.
NEUTRAL
Impact 3/10
Horizondays Processed3mo ago SEC9999999995-26-002258
IPO/offering going effective
Actionable Insight • Neutral

Monitor for a prospectus or pricing announcement in the coming days to determine the offering size and terms. The effectiveness of a registration statement typically precedes pricing by 1-2 days for IPOs or immediate shelf takedowns. Recent insider selling of $1.2M over 30 days warrants attention for potential dilution concerns.

DirectionNeutral
Confidencelow
Horizondays
Final — all horizons settled through T+60d
CBIO ▼ -13.51% at T+60d
NEUTRAL call -13.51% · α vs SPY -17.51% · entry $15.69 → $13.57
Entry = T+0 close
Jul 13, 2026
via day close
T+1d
-2.45%
call -2.45% · α -2.81%
$15.31
settled 4mo ago
T+5d
-5.99%
call -5.99% · α -5.21%
$14.75
settled 3mo ago
T+20d
+10.45%
call +10.45% · α +7.27%
$17.33
settled 3mo ago
T+60d
-13.51%
call -13.51% · α -17.51%
$13.57
settled 21d ago

Price Chart

Loading chart...

Executive Summary

Analysis based on filing metadata only — document content was unavailable. Crescent BioPharma's registration statement has become effective (EFFECT notice), which typically allows the company to proceed with a securities offering. Without the actual filing content, the specific type of offering (IPO, follow-on, or shelf) and its terms cannot be determined.

Key Facts

  • Filing document content was unavailable — analysis based on metadata only
  • EFFECT notice indicates a registration statement has been declared effective by the SEC
  • Company has a market cap of $478M and 87% analyst bullish consensus
  • Recent insider activity shows 7 sells totaling $1.2M over the past 30 days

Financial Impact

Unknown — filing content unavailable

Risk Factors

  • Dilution risk if this is a shelf registration that becomes available for immediate share sales
  • Insider selling pattern of $1.2M over 30 days may indicate management concerns about valuation

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
87% bullish (15 analysts)

Investment Themes

Documents Analyzed

Report based on filing metadata.

16 reports for CBIO
Performance horizon
75% Hit rate @ T+60 3 of 4 directional calls Went positive at some point 4 of 4 best @ T+60▲ +9.89%Jul 14, 2026
Filters
Rows
Reports for CBIO — sortable, filterable
TypeNow
Oct 15, 2026
11d ago
8-K
NEUTRAL ★ 3/10
$11.84awaiting T+60—$12.76 (+7.77%)
Oct 15, 2026
11d ago
Press Release
NEUTRAL ★ 4/10
$11.84awaiting T+60—$12.76 (+7.77%)
Oct 5, 2026
21d ago
Press Release
NEUTRAL ★ 4/10
$13.94awaiting T+60—$12.76 (−8.46%)
Sep 18, 2026
5w ago
Insider Cluster
NEUTRAL ★ 3/10
$16.25awaiting T+60—$12.76 (−21.48%)
Jul 30, 2026
12w ago
8-K
NEUTRAL ★ 3/10
$15.02 $12.82▼ −14.65%▼ −17.11%$12.76 (−15.05%)
Jul 20, 2026
14w ago
Insider Buy
BULLISH ★ 7/10
$16.64 $12.91▼ −22.42%▼ −26.39%$12.76 (−23.32%)
Jul 15, 2026
14w ago
8-K / 424B5
BEARISH ★ 6/10
$15.11 $14.91▲ +1.32%▲ +5.03%$12.76 (+15.55%)
Jul 14, 2026
14w ago
Press Release
BEARISH ★ 7/10
$15.67 $14.12▲ +9.89%▲ +12.42%$12.76 (+18.57%)
Jul 14, 2026
14w ago
424B5
BEARISH ★ 6/10
$15.67 $14.12▲ +9.89%▲ +12.42%$12.76 (+18.57%)
Jul 13, 2026
15w ago
EFFECT
NEUTRAL ★ 3/10
$15.69 $13.57▼ −13.51%▼ −17.51%$12.76 (−18.67%)
Showing 10 of 16

US Market Status

Market Closed — Opens in 6h

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 13, 2026